Geron Corporation (BIT:1GERN)
Italy · Delayed Price · Currency is EUR | Market Cap | 668.18M -4.8% |
| Revenue (ttm) | 179.05M +24.4% |
| Net Income | -59.18M |
| EPS | -0.09 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 90.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1.071 |
| Previous Close | 1.071 |
| Day's Range | 1.071 - 1.071 |
| 52-Week Range | 0.938 - 1.624 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About Geron
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clini... [Read more]
Financial Performance
In 2025, Geron's revenue was $183.88 million, an increase of 138.83% compared to the previous year's $76.99 million. Losses were -$83.50 million, -52.17% less than in 2024.
Financial numbers in USD Financial StatementsNews
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced...
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood c...
Geron Transcript: H.C. Wainwright 28th Annual Global Investment Conference
RYTELO has achieved record quarterly sales and is on track for $230–$240 million in 2026 revenue, driven by strong community adoption and expanding first- and second-line use. International expansion and pivotal myelofibrosis trial results are key upcoming catalysts.
Geron Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Revenue growth remains strong with guidance raised to $230–$240 million and profitability in sight. Expansion efforts target deeper community penetration and international markets, while a pivotal myelofibrosis trial advances with regulatory engagement.
Geron to Present at Upcoming Investor Conferences
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood c...
Geron Earnings Call Transcript: Q2 2026
Q2 2026 saw robust net revenue growth and expanding RYTELO adoption, with strong financial discipline and a solid cash position. Real-world evidence reinforced RYTELO's efficacy, and regulatory and commercial strategies are advancing in the U.S. and Europe.
Geron Earnings release: Q2 2026
Geron released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Geron Quarterly report: Q2 2026
Geron has published its Q2 2026 quarterly earnings report on August 5, 2026.
Geron reports Q2 EPS (2c), consensus (1c)
Reports Q2 revenue $57.48M, consensus $55.38M. “We are executing a focused strategy to build a leading hematology company, which starts with bringing RYTELO to more eligible patients impacted by LR-MD...
Geron sees FY26 revenue $220M-$240M, consensus $234.22M
The company said, “For fiscal year 2026, the Company expects RYTELO net product revenue to be in the range of $220 million to $240 million. Geron (GERN) also expects total…
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Achieved $57.5 million in RYTELO ® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product revenue and total operating expenses expected ...
Geron Slides: Corporate presentation
Geron has posted slides in relation to its latest quarterly earnings report, which was published on August 2, 2026.
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, tod...
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to ...
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a s...
Geron appoints Chinmaya Rath as chief business officer
Geron (GERN) announced the appointment of Chinmaya Rath as chief business officer. Most recently, he served as head of pharma solutions at Cellworks and chief business officer at GlycoMimetics. Publis...
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies Mr. Rath brings senior leadership experience in business development across a range o...
Geron Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
RYTELO’s adoption is rising, driven by focused education and strategic targeting of community physicians. Real-world data supports its efficacy and safety, while ongoing trials and a strong cash position underpin future growth and expansion in hematology.
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, tod...
Geron Transcript: AGM 2026
The meeting approved all board proposals, including director elections and incentive plan changes. Updates highlighted progress in clinical trials, organizational restructuring, and plans for ex-U.S. commercialization, with key trial results expected by 2028.
Geron Transcript: Stifel 2026 Targeted Oncology Virtual Forum
RYTELO's commercial rollout is accelerating, with updated NCCN guidelines supporting second-line use and strong uptake in community settings. Real-world and long-term data reinforce efficacy and safety, while financial guidance points to near-term profitability and strategic optionality.
Geron Transcript: Bank of America Global Healthcare Conference 2026
RYTELO continues to gain traction in low-risk MDS, with strong Q1 revenue and expanding use in the second-line setting. Real-world evidence supports clinical trial results, and an interim readout for imetelstat in myelofibrosis is expected later this year.
Geron to present RWE study of RYTELO at EHA Congress
Geron (GERN) Corporation announced that the first real-world evidence study of RYTELO in patients with lower-risk myelodysplastic syndromes will be presented at the European Hematology Association 202...
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026
Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population